Inari Medical, Inc. (NARI)
- Previous Close
38.18 - Open
37.50 - Bid 37.94 x 100
- Ask 38.08 x 300
- Day's Range
37.46 - 38.57 - 52 Week Range
36.73 - 71.85 - Volume
844,286 - Avg. Volume
1,214,853 - Market Cap (intraday)
2.207B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
72.09
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
www.inarimedical.comRecent News: NARI
Performance Overview: NARI
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NARI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NARI
Valuation Measures
Market Cap
2.21B
Enterprise Value
2.13B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.39
Price/Book (mrq)
4.76
Enterprise Value/Revenue
4.31
Enterprise Value/EBITDA
140.31
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.33%
Return on Assets (ttm)
-0.38%
Return on Equity (ttm)
-0.37%
Revenue (ttm)
493.63M
Net Income Avi to Common (ttm)
-1.64M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
115.45M
Total Debt/Equity (mrq)
6.89%
Levered Free Cash Flow (ttm)
38.7M
Research Analysis: NARI
Company Insights: NARI
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NARI
NARI: Lowering target price to $39.00
INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetNARI: Lowering target price to $41.00
INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetNARI: Lowering target price to $45.00
INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetNARI: What does Argus have to say about NARI?
INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $48.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target